A RANDOMIZED DOUBLE-BLIND PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM- BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NON-MUCINOUS EPITHELIAL OVARIAN CANCER

Brief description of study

You are being asked to be in this research study because you have ovarian cancer. The current standard of care (SOC) for the treatment of ovarian cancer is paclitaxel and carboplatin, with or without bevacizumab. Your Study Doctor will determine if you should receive bevacizumab with paclitaxel and carboplatin. This study is being done to determine if adding the investigational drugs (TSR-042 - immunotherapy and niraparib - PARP inhibitor) to SOC delays or prevents ovarian cancer from coming back.


Clinical Study Identifier: s18-00572
ClinicalTrials.gov Identifier: NCT03602859
Principal Investigator: Bhavana Pothuri.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.